INTRODUCTION {#s1}
============

With 238,700 new cases worldwide, ovarian cancer was the seventh most frequently occurring cancer among women in 2012, and was responsible for 151,900 deaths. In developing countries, newly diagnosed cases of ovarian cancer have exceeded those of cervical cancer \[[@R1]\]. Moreover, mortality from ovarian cancer has decreased by only 1.29 per 100,000 over the past several decades due in large part to the paucity of effective screening methods and chemopreventive agents, and to its being asymptomatic during early stages \[[@R2], [@R3]\]. Although active surgical treatment and adjuvant chemotherapy have been applied to the treatment of advanced ovarian cancer, the prognosis of the patients remains poor with a 5-year survival rate of only 23% \[[@R4], [@R5]\]. Considerable research has focused on explaining the molecular mechanisms underlying ovarian cancer, but in the absence of an appropriate progression model, they remain far from clear \[[@R6], [@R7]\]. Thus, identification of a sensitive and early-detected biomarker useful for cancer prediction and prevention is badly needed.

*TP53* is a tumor suppressor gene is located on the chromosome 17p13 short arm and encodes a protein with 393 amino acids \[[@R8]\]. Its product, p53, is regarded as a major inhibitor of tumorigenesis, which is involved in cycle arrest, DNA repair, apoptosis or cellular aging \[[@R9], [@R10]\]. Mutations in *TP53* can result in Li--Fraumeni syndrome, which increases the risk of diverse cancers, including breast cancer, carcinosarcoma, leukemia and brain tumors, among others \[[@R11]\]. In addition to the tumor-associated *TP53* mutations, polymorphisms also have an important impact on the susceptibility to cancer \[[@R12]--[@R15]\]. The well-studied *TP53* polymorphism is at codon 72 of exon 4 (CGC to CCC) and corresponds to a change from arginine to proline \[[@R16], [@R17]\]. The two polymorphic forms of *TP53* exhibit differences in their biological function. Whereas the Arg72 form induces cell apoptosis upon stress and inhibits tumorigenesis, the Pro72 inhibits the G1 phase of cell cycle progression \[[@R18]\]. There has been much research on the relationship between *TP53* codon 72 polymorphism and ovarian cancer risk, but the results are conflicting and inconsistent. Some studies have shown that the *TP53* Arg allele is associated with a higher risk of ovarian cancers \[[@R19]--[@R21]\], while others found that the *TP53* Pro allele is likely a risk factor for ovarian cancer \[[@R22]--[@R24]\]. In addition, there are also publications suggesting the *TP53* Arg72Pro polymorphism is not associated with susceptibility to ovarian cancer \[[@R25], [@R26]\]. The reasons for the contradictory results may be attributable to inadequate sample size, different sources of DNA, ethnicity, different environmental exposures, or the borderline effect of genetic variant. In an effort to increase clarity, we collected all eligible studies and analyzed the potential effect of TP53 codon 72 polymorphism on the susceptibility to ovarian cancer.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

Through searches of the PubMed, EMBASE and Chinese Biomedical (CBM) databases, a total of 424 potentially relevant articles were initially identified. Of those, 386 were excluded, and 38 were chosen for further evaluation through checking of the title and abstract (Figure [1](#F1){ref-type="fig"}). Based on the inclusion criteria described below in the Methods, 18 articles were included in the final analysis \[[@R19], [@R20], [@R22]--[@R36]\]. Among those 18, the publication by Schildkraut et al. \[[@R26]\] investigated the genotype distributions of the *TP53* Arg72Pro polymorphism in different areas, so it was divided into seven separate studies. Overall, 24 case-control studies with 3271 cases (13 to 626 per study) and 6842 controls (13 to 1045 per study) were included in the present meta-analysis. The main characteristics of all the included studies are presented in Table [1](#T1){ref-type="table"}. Among these studies, 19 were conducted with Caucasians, four with Asians, and only one with Africans. Because detailed information about the source of the controls were not been provided in the study by Peller et al. \[[@R36]\], only 12 articles were classified as population-based, and 11 were hospital-based. In addition, 15 studies with a quality score ≥ 9 were considered to be high quality, while nine with a score \< 9 were regarded as low quality. Table [1](#T1){ref-type="table"} also summarizes the distribution of genotypes, minor allele frequencies (MAFs) and the Hardy--Weinberg equilibrium (HWE) in the controls.

![Flowchart of included studies](oncotarget-08-112761-g001){#F1}

###### Characteristics of studies included in the current meta-analysis

  Surname             Year   Country        Ethnicity   Design         Genotyping method   Case   Control   MAF   HWE   Score                                     
  ------------------- ------ -------------- ----------- -------------- ------------------- ------ --------- ----- ----- ------- ----- ----- ------ ------ ------- ----
  Buller              1997   USA            Caucasian   PB             PCR-SSCP            98     79        13    190   30      18    4     52     0.25   0.579   10
  Peller              1999   Israel         Caucasian   Not detailed   DS                  7      6         0     13    8       5     0     13     0.19   0.447   5
  Hogdall             2002   Denmark        Caucasian   PB             PCR-RFLP            118    73        20    211   48      27    8     83     0.26   0.165   9
  Li                  2002   China          Asian       PB             PCR-RFLP            14     20        5     39    29      67    35    131    0.52   0.920   10
  Qie                 2002   China          Asian       HB             PCR-RFLP            10     18        2     30    12      16    2     30     0.33   0.273   5
  Pegoraro            2003   South Africa   African     HB             AS-PCR              9      29        25    63    32      147   161   340    0.69   0.852   6
  Agorastos           2004   Greece         Caucasian   HB             PCR                 26     22        3     51    6       19    5     30     0.48   0.142   5
  Kang                2004   China          Asian       HB             PCR                 28     60        36    124   37      64    27    128    0.46   0.945   9
  Morari              2006   Brazil         Caucasian   PB             AS-PCR              23     46        0     69    117     91    14    222    0.27   0.505   9
  Santos              2006   Portugal       Caucasian   HB             AS-PCR              49     40        10    99    117     58    13    188    0.22   0.128   7
  Ueda                2006   Japan          Asian       HB             PCR-RFLP            21     41        6     68    34      54    7     95     0.36   0.021   6
  Schildkraut-POCS    2009   Poland         Caucasian   PB             TaqMan              51     63        4     118   368     207   45    620    0.24   0.038   11
  Schildkraut-NCOCS   2009   USA            Caucasian   PB             IGGA                132    104       16    252   231     182   24    437    0.26   0.122   13
  Schildkraut-MAYO    2009   USA            Caucasian   PB             IGGA                96     82        14    192   261     157   37    455    0.25   0.057   13
  Schildkraut-AUS     2009   Australia      Caucasian   PB             MassARRAY           121    59        14    194   219     110   31    360    0.24   0.002   11
  Schildkraut-HAW     2009   USA            Caucasian   PB             TaqMan              18     12        0     30    78      60    8     146    0.26   0.416   12
  Schildkraut-MAL     2009   Denmark        Caucasian   PB             TaqMan              134    94        25    253   564     371   78    1013   0.26   0.123   14
  Schildkraut-SEA     2009   New-England    Caucasian   PB             TaqMan              119    75        18    212   461     326   55    842    0.26   0.796   14
  Matei               2012   Roman          Caucasian   HB             PCR-RFLP            9      6         6     21    7       7     7     21     0.50   0.127   4
  Dholariya           2013   North India    Caucasian   HB             ASO-PCR             33     50        17    100   62      32    6     100    0.22   0.499   9
  Malisic             2013   Serbia         Caucasian   HB             PCR-RFLP            22     22        3     47    45      22    3     70     0.20   0.881   6
  Medrek              2013   Poland         Caucasian   PB             TaqMan              302    265       59    626   537     436   72    1045   0.28   0.191   12
  Tecza               2015   Poland         Caucasian   HB             PCR-RFLP            130    79        16    225   167     150   24    341    0.29   0.213   11
  Benhessou           2016   Morocco        Caucasian   HB             AS-PCR              33     10        1     44    43      27    10    80     0.29   0.095   5

AA, Arg/Arg; AP, Arg/Pro; PP, Pro/Pro; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; PB, population based; HB, hospital based; PCR, polymerase chain reaction; PCR-RFLP, PCR-restriction fragment length polymorphism; AS-PCR, allele-specific PCR; ASO-PCR, allele specific oligonucleotide; IGGA, Illumina golden gate assay; DS, direct sequencing; PCR-SSCP, PCR-single-strand conformation polymorphism assay.

Meta-analysis {#s2_2}
-------------

As shown in Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}, the overall pooled analysis indicated no significant association between *TP53* Arg72Pro polymorphism and ovarian cancer risk in any of the five genetic models \[homozygous: odds ratio (OR)=1.04, 95% confidence interval (CI)=0.81-1.34; heterozygous: OR=1.14, 95% CI=0.96-1.36; recessive: OR=1.05, 95% CI=0.90-1.22; dominant: OR=1.12, 95% CI=0.94-1.33 and allele comparing: OR=1.06, 95% CI=0.93-1.20). In addition, when we performed subgroup analyses based on ethnicity, source of controls, and quality of studies, there were again no significant results indicating a relationship between the *TP53* Arg72Pro polymorphism and ovarian cancer risk.

###### Meta-analysis of the association between *TP53* codon 72 (rs1042522 G\>C) polymorphism and ovarian cancer risk

  Variables           No. ofstudies   Samplesize   Homozygous         Heterozygous   Recessive          Dominant   Allele                                                                       
  ------------------- --------------- ------------ ------------------ -------------- ------------------ ---------- -------------------- ------- ------------------ --------- ------------------ ---------
  All                 24              3271/6842    1.04 (0.81-1.34)   0.015          1.14 (0.96-1.36)   \<0.001    1.05 (0.90-1.22)     0.131   1.12 (0.94-1.33)   \<0.001   1.06 (0.93-1.20)   \<0.001
  Ethnicity                                                                                                                                                                                     
  Caucasians          19              2947/6118    1.09 (0.84-1.43)   0.035          1.18 (0.97-1.43)   \<0.001    1.09 (0.91-1.29)     0.177   1.15 (0.95-1.39)   \<0.001   1.09 (0.95-1.25)   \<0.001
   Asians             4               261/384      0.99 (0.40-2.42)   0.070          1.08 (0.75-1.56)   0.508      1.07 (0.70-1.65)     0.166   1.06 (0.67-1.68)   0.190     1.02 (0.69-1.49)   0.062
   Africans           1               63/340       0.55 (0.24-1.29)   ---            0.70 (0.30-1.63)   ---        0.73 (0.42-1.27)     ---     0.62 (0.28-1.38)   ---       0.76 (0.51-1.12)   ---
  Source of control                                                                                                                                                                             
   PB                 12              2386/5406    1.08 (0.86-1.36)   0.306          1.18 (0.98-1.41)   0.006      1.03 (0.86-1.25)     0.200   1.15 (0.98-1.34)   0.030     1.09 (0.99-1.19)   0.262
   HB                 11              872/1423     1.06 (0.61-1.84)   0.004          1.05 (0.71-1.55)   \<0.001    1.08 (0.83-1.40)     0.135   1.03 (0.67-1.57)   \<0.001   1.02 (0.75-1.39)   \<0.001
  Quality score                                                                                                                                                                                 
   ≥9                 15              2835/5975    1.13 (0.88-1.47)   0.054          1.19 (0.98-1.44)   \<0.001    1.11 (0. 94-1. 32)   0.124   1.17 (0.98-1.41)   \<0.001   1.11 (0.98-1.25)   0.002
   \<9                9               436/867      0.77 (0.39-1.49)   0.064          0.98 (0.63-1.50)   0.033      0.81 (0.56-1.16)     0.425   0.91 (0.56-1.47)   0.004     0.91 (0.64-1.29)   0.002

Het, heterogeneity; OR, odds ratio; CI, confidence interval; HB, hospital based; PB, population based.
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Heterogeneity and sensitivity analyses {#s2_3}
--------------------------------------

As shown in Table [2](#T2){ref-type="table"}, significant heterogeneities were observed among studies in the homozygous (*P* = 0.015), heterozygous (*P* \< 0.001), recessive (*P* = 0.131) and dominant (*P* \< 0.001) models, as well as with allele comparing (*P* \< 0.001). We adopted the random-effects model to solve the significant heterogeneity between studies, because it generated wider CIs to estimate genetic susceptibility. To confirm the impact of each study on summary ORs, sensitivity analysis was conducted by separately omitting each single study involved in the analysis and recalculating ORs and the 95% CIs. This analysis showed our results to be statistically robust, as the corresponding pooled ORs and 95% CIs were not materially changed by any of the omissions (data not shown).

Publication bias {#s2_4}
----------------

In this meta-analysis, publication bias was assessed using Begg\'s and Egger\'s tests (Figure [3](#F3){ref-type="fig"}). The results demonstrated that there was no potential publication bias present in the included articles under three genetic models (heterozygous: *P* = 0.945; dominant model: *P* = 0.752 and allele comparing model: *P* = 0.371). However, it was important to note that obvious bias existed in the other two models (homozygous: *P* = 0.027 and recessive model: *P* = 0.032). The reason for the bias may be related to the small sample size so that no single study was considered to be the cause of the publication bias.
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DISCUSSION {#s3}
==========

The tumor-suppressor protein p53 is a well-known deterrent to cell growth, which inhibits tumorigenesis by activating apoptotic machinery \[[@R37]\]. *TP53* Arg72Pro, a common *TP53* polymorphism, induces certain conformational p53 mutants and binds stably to another tumor suppressor, p73 \[[@R38], [@R39]\]. The two polymorphic variants of *TP53* exert different biochemical and biological effects on cell cycle progression. The Arg72 form induces higher levels of apoptosis than the Pro72 form, while the Pro72 form has the ability to induce growth arrest during the G1 phase of the cell cycle \[[@R40]\]. We therefore hypothesized that *TP53* Arg72Pro polymorphism may be closely related to the risk of ovarian cancer. Although numerous studies have investigated the relationship between the *TP53* Arg72Pro polymorphism and ovarian cancer risk, the results have been inconsistent. Hence, the current meta-analysis of 24 studies was employed further investigate the association between *TP53* Arg72Pro polymorphism and ovarian cancer, which is the most comprehensive analysis to date. The overall pooled results suggest there is no significant connection between the *TP53* Arg72Pro polymorphism and ovarian cancer risk in five genetic models. This result was further confirmed in analyses stratified based on ethnicity, source of control and quality score. Consistent with the results of present meta-analysis, some earlier studies found that there is little or no association between *TP53* Arg72Pro polymorphism and ovarian cancer risk. Likewise, an previous meta-analysis conducted by Francisco et al. \[[@R41]\] detected no association between the *TP53* Arg72Pro polymorphism and ovarian cancer risk under any genetic model, and stratified analyses also failed to validate a genetic association. On the other hand, a study by Shen et al. \[[@R42]\] concluded that the *TP53* Arg72 allele was associated with a modest, but significantly reduced risk of ovarian cancer when the included studies were classified as high quality. In yet another analysis, the main findings of 19 case-control studies, including 2,240 cases and 5,246 controls, were similar to those of the present study, though the subgroup analysis indicated a marginal association between the *TP53* Arg72Pro polymorphism and ovarian cancer risk in the heterozygote model in Caucasians \[[@R43]\].

One possible explanation for why it is difficult to detect an effect of *TP53* codon 72 polymorphism on ovarian cancer based on these epidemiological results is that there was loss of heterozygosity (LOH) at the *TP53* locus. Based on the previous publications, the *TP53* Arg allele is preferentially mutated and expressed, while the Pro allele is lost in *TP53* Arg72/Pro72 heterozygotes across several cancer types \[[@R44], [@R45]\]. Thus the results of these genetic association studies may be biased by preferential LOH of the Pro allele. In addition, the results were probably influenced by individual infections with tumor-associated human papillomaviruses (HPVs). Storey found that the Arg 72 isoform was more susceptible to degradation by E6 protein of HPV16 than Pro 72 isoform in a heterozygous situation \[[@R46]\]. However, the original data on HPV infection were unavailable from the included studies, so further stratified analysis based on HPV infection status was not done.

The merits of the present meta-analysis in the context of the previously published ones are as follows. (a) We used an expanded retrieval range that included the latest studies and minimized selection bias. (b) There was a larger sample size and greater statistical power. (c) Our study is further verification that the *TP53* Arg72Pro polymorphism has no impact on ovarian cancer risk. Nonetheless, there are still several limitations to the present meta-analysis. First, the sample sizes of many of the included studies were small, which contributed to reducing the statistical power of the genetic association estimate. Second, this meta-analysis only included publications in English and Chinese, which could lead to selection bias. Third, there were three studies in which the detected genotype frequencies deviated from the HWE \[[@R26], [@R31]\], making biased results inevitable. Fourth, significant heterogeneity was present under four genetic models, which may be attributable to ethnic differences and/or variation in sample size, study design or genotyping methods. Fifth, the well-known protective factors for ovarian cancer, such as bearing children, oral contraceptives and breastfeeding, were not taken into account due to a lack of individual information. Finally, we did not consider the possibility of the gene-gene interaction.

Despite of these limitations, the pooled results demonstrated that there was no significant association between the *TP53* Arg72Pro polymorphism and ovarian cancer risk. Future well-designed studies that include large samples and take environmental factors into account will be necessary to validate our findings.

MATERIALS AND METHODS {#s4}
=====================

Identification of relevant studies {#s4_1}
----------------------------------

We conducted a search of the PubMed, EMBASE and Chinese Biomedical (CBM) databases using the following keywords: "*TP53* or *p53*", "polymorphism or variant or variation" and "ovarian" (prior to May 1, 2017). In addition, the references lists of the original articles and reviews were checked manually to identify additional studies. For overlapping data and republished studies, only the latest and largest studies were included in the current meta-analysis.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Inclusion criteria for studies were as follows: (a) evaluation of the association between the *TP53* gene Arg72Pro polymorphism and ovarian cancer risk, (b) case-control design, (c) sufficient and adequate data provided to calculate crude OR and 95% CI, (d) the data were reported in English or Chinese.

Studies were excluded for the following reasons: (a) duplicate publication, (b) cases only studies, or (c) article was a review, case report, editorial or expert opinion.

Data extraction {#s4_3}
---------------

Two reviewers (Anqi Zhang and Jing He) assessed weather the retrieved studies met the inclusion criteria, and extracted data from each eligible study. If the two reviewers did not separately reach a unanimous decision on any one item, the dispute was resolved by joint review and consensus. The information retrieved from each study was as follows: the first author\'s surname, publication data, country of origin, ethnicity, source of control, total number of cases and controls, genotype methods, and numbers of cases and controls for the *TP53* Arg72Pro. Based on differently stratified analyses, ethnicity was divided into three categories: Asians, Caucasians and Africans, and controls were divided into hospital-based and population-based.

Statistical methods {#s4_4}
-------------------

The strength of the association between *TP53* Arg72Pro polymorphism and ovarian cancer susceptibility was recalculated using crude ORs with the corresponding 95% CIs. The pooled ORs were calculated for the homozygous (Pro/Pro vs. Arg/Arg), heterozygous (Arg/Pro vs. Arg/Arg), dominant \[(Arg/Pro + Pro/Pro) vs. Arg/Arg\], and recessive \[Pro/Pro vs. (Arg/Pro + Arg/Arg)\] models, as well as allele comparison (Pro vs. Arg). The Chi square-based Q test was used to calculate the heterogeneity between studies. If the *P* value was less than 0.1, the pooled ORs were calculated using a random-effects model (the DerSimonian and Laird method) \[[@R47]\]. Otherwise, a fixed-effect model (the Mantel--Haenszel method) was chosen for further calculation \[[@R48]\]. Subgroup analyses were classified into three parts: ethnicity, study design and quality score. The quality score for each study was assessed in accordance with the evaluation criteria, as described previously \[[@R49]--[@R51]\]. The quality scores ranged from 0 to 15, with scores ≥ 9 defined as high quality, while \< 9 were defined as low quality. Publication bias was assessed by constructing a funnel plots, after which the asymmetry of the funnel plots was assessed using Egger\'s linear regression test \[[@R52]\]. HWE was evaluated using the chi-square-based Q-test, values of *P* \< 0.05 were regarded as deviations from the HWE. All statistical tests were conducted using STATA software (version 11.0; Stata Corporation, College Station, TX). Values of *P* \< 0.05 was considered significant, and all tests were two-sided.
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